Pipeline

We are leveraging our proprietary kinase switch control inhibitor platform to develop a pipeline of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers. We currently retain global development and commercialization rights to our drug candidates.

Tumor-Targeted Programs and Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Global Rights
DCC-2618 KIT & PDGFRα

GIST

 

 

 

Deciphera
PDGFRα

GBM & Glioma

 

 

 

Deciphera
KIT (D816V)

Advanced Systemic Mastocytosis

 

 

 

Deciphera
KIT & PDGFRα

Other Cancers

 

 

 

Deciphera
Research Program Undisclosed

Cancer Metabolism
Deciphera
Immunokinase Programs and Indications
Rebastinib TIE2

Breast Cancer + Chemotherapy

 

 

 

Deciphera
TIE2

Checkpoint Inhibitor Combination

 

 

 

Deciphera
DCC-3014 CSF1R

Solid Tumors & Hematological Malignancies

 

 

 

Deciphera
CSF1R

Checkpoint Inhibitor Combination

 

 

 

Deciphera
Research Program Undisclosed

Immunokinase
Deciphera
Tumor-Targeted Programs and Indications
Phase Global Rights
DCC-2618
KIT & PDGFRα

GIST

 

Phase 1 Deciphera
PDGFRα

GBM & Glioma

 

Phase 1 Deciphera
KIT (D816V)

Advanced Systemic Mastocytosis

 

Phase 1 Deciphera
KIT & PDGFRα

Other Cancers

 

Phase 1 Deciphera
Research Program
Undisclosed

Cancer Metabolism
Pre-Clinical Deciphera
Immunokinase Programs and Indications
Phase Global Rights
Rebastinib
TIE2

Breast Cancer + Chemotherapy

 

Phase 1 Deciphera
TIE2

Checkpoint Inhibitor Combination

 

Phase 1 Deciphera
DCC-3014
CSF1R

Solid Tumors & Hematological Malignancies

 

Phase 1 Deciphera
CSF1R

Checkpoint Inhibitor Combination

 

Phase 1 Deciphera
Research Program
Undisclosed

Immunokinase
Pre-Clinical Deciphera